Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitrine Study Group.

Inhaled nitric oxide (iNO), a selective pulmonary vasodilator and intravenously administered almitrine, a selective pulmonary vasoconstrictor, have been shown to increase PaO2 in patients with acute respiratory distress syndrome (ARDS). This prospective study was undertaken to assess the cardiopulmonary effects of combining both drugs. In 48 consecutive patients with early ARDS, cardiorespiratory parameters were measured at control, after iNO 5 ppm, after almitrine 4 micrograms. kg-1. min-1, and after the combination of both drugs. In 30 patients, dose response to 2, 4, and 16 micrograms. kg-1. min-1 of almitrine with and without NO was determined. Almitrine and lactate plasma concentrations were measured in 17 patients. Using pure O2, PaO2 increased by 75 +/- 8 mm Hg after iNO, by 101 +/- 12 mm Hg after almitrine 4 micrograms. kg-1. min-1, and by 175 +/- 18 mm Hg after almitrine combined with iNO (p < 0.001). In 63% of the patients, PaO2 increased by more than 100% with the combination of both drugs. Mean pulmonary artery pressure (Ppa) increased by 1.4 +/- 0.2 mm Hg with almitrine 4 micrograms/kg/ min (p < 0.001) and decreased by 3.4 +/- 0.4 mm Hg with iNO and by 1.5 +/- 0.3 mm Hg with the combination (p < 0.001). The maximum increase in PaO2 was obtained at almitrine concentrations <= 4 micrograms. kg-1. min-1, whereas almitrine increased Ppa dose-dependently. Almitrine plasma concentrations also increased dose-dependently and returned to values close to zero after 12 h. In many patients with early ARDS, the combination of iNO 5 ppm and almitrine 4 micrograms. kg-1. min-1 dramatically increases PaO2 without apparent deleterious effect allowing a rapid reduction in inspired fraction of O2. The long-term consequences of this immediate beneficial effect remain to be determined.

[1]  P. Morrow,et al.  Inhalation of 0.30 ppm nitrogen dioxide potentiates exercise-induced bronchospasm in asthmatics. , 2015, The American review of respiratory disease.

[2]  J. West,et al.  Enhancement of hypoxic pulmonary vasoconstriction by almitrine in the dog. , 2015, The American review of respiratory disease.

[3]  J. Saffle,et al.  Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. , 1998, American journal of respiratory and critical care medicine.

[4]  E. Troncy,et al.  Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. , 1998, American journal of respiratory and critical care medicine.

[5]  C. Carvalho,et al.  Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. , 1998, The New England journal of medicine.

[6]  L. Puybasset,et al.  Inhaled nitric oxide in acute respiratory distress syndrome with and without septic shock requiring norepinephrine administration: a dose–response study , 1997, Critical care.

[7]  L. Puybasset,et al.  Distribution of inhaled nitric oxide during sequential and continuous administration into the inspiratory limb of the ventilator , 1997, Intensive Care Medicine.

[8]  K. Geiger,et al.  Hypoxic Pulmonary Vasoconstriction in Nonventilated Lung Areas Contributes to Differences in Hemodynamic and Gas Exchange Responses to Inhalation of Nitric Oxide , 1997, Anesthesiology.

[9]  K. Geiger,et al.  Effect of inhaled nitric oxide on venous admixture depends on cardiac output in patients with acute lung injury and acute respiratory distress syndrome , 1996, Acta anaesthesiologica Scandinavica.

[10]  G. Rich,et al.  The Response to Varying Concentrations of Inhaled Nitric Oxide in Patients with Acute Respiratory Distress Syndrome , 1996, Anesthesia and analgesia.

[11]  T. Loop,et al.  Inhaled Nitric Oxide Reduces Pulmonary Transvascular Albumin Flux in Patients with Acute Lung Injury , 1995, Anesthesiology.

[12]  E. Vicaut,et al.  Dose‐Response Curves of Inhaled Nitric Oxide with and without Intravenous Almitrine in Nitric Oxide‐responding Patients with Acute Respiratory Distress Syndrome , 1995, Anesthesiology.

[13]  L. Puybasset,et al.  Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure. , 1995, American journal of respiratory and critical care medicine.

[14]  P. Soler,et al.  Mechanical ventilation-induced pulmonary edema. Interaction with previous lung alterations. , 1995, American journal of respiratory and critical care medicine.

[15]  J. D. Young,et al.  Inhaled nitric oxide in acute respiratory failure in adults. , 1994, British journal of anaesthesia.

[16]  L. Puybasset,et al.  Inhaled Nitric Oxide Reverses the Increase in Pulmonary Vascular Resistance Induced by Permissive Hypercapnia in Patients with Acute Respiratory Distress Syndrome , 1994, Anesthesiology.

[17]  J. D. Young,et al.  Dose-response relationship for inhaled nitric oxide in experimental pulmonary hypertension in sheep. , 1993, British journal of anaesthesia.

[18]  D. Payen,et al.  Almitrine effect on nitric oxide inhalation in adult respiratory distress syndrome , 1993, The Lancet.

[19]  R. Rossaint,et al.  Inhaled nitric oxide for the adult respiratory distress syndrome. , 1993, New England Journal of Medicine.

[20]  R. Froidevaux,et al.  A comparative study of the effects of almitrine bismesylate and lateral position during unilateral bacterial pneumonia with severe hypoxemia. , 1992, The American review of respiratory disease.

[21]  N. Voelkel,et al.  Almitrine mimics hypoxic vasoconstriction in isolated rat lungs. , 1992, The American journal of physiology.

[22]  C. Mélot,et al.  Almitrine and doxapram in experimental lung injury. , 1992, The American review of respiratory disease.

[23]  J. Wain,et al.  Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction , 1991, Circulation.

[24]  T. Sandström,et al.  Inflammatory cell response in bronchoalveolar lavage fluid after nitrogen dioxide exposure of healthy subjects: a dose-response study. , 1991, The European respiratory journal.

[25]  B. Marshall,et al.  Low‐Dose Almitrine Bismesylate Enhances Hypoxic Pulmonary Vasoconstriction in Closed‐Chest Dogs , 1990, Anesthesia and analgesia.

[26]  C. Mélot,et al.  Restored hypoxic pulmonary vasoconstriction by peripheral chemoreceptor agonists in dogs. , 1990, The American review of respiratory disease.

[27]  A. Cutillo,et al.  Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease. , 1989, The American review of respiratory disease.

[28]  J F Murray,et al.  An expanded definition of the adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[29]  J. Roca,et al.  Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[30]  B. Marshall,et al.  High‐dose Almitrine Bismesylate Inhibits Hypoxic Pulmonary Vasoconstriction in Closed‐chest Dogs , 1987, Anesthesiology.

[31]  J. Degos,et al.  PERIPHERAL NEUROPATHY IN PATIENTS TREATED WITH ALMITRINE DIMESYLATE , 1985, The Lancet.

[32]  D. Matamis,et al.  Total respiratory pressure-volume curves in the adult respiratory distress syndrome. , 1984, Chest.

[33]  M H Weil,et al.  Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. , 1967, Clinical chemistry.

[34]  J. Zimmerman,et al.  Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. , 1998, Critical care medicine.